* New HIV Prevention jab Available on NHS: England and wales will now offer a long-acting injectable HIV prevention medication (cabotegravir, or CAB-LA) on the NHS, aligning with Scotland's existing policy.
* How it effectively works: The injection is given six times a year (or every other month) and provides an option to daily HIV prevention pills (PrEP).
* Goal: This new option aims to help the UK achieve its goal of ending new HIV cases by 2030.
* Future Potential: Early results suggest another injection, lenacapavir, could potentially lead to annual HIV prevention jabs.
* Benefits of the Jab: The injection offers convenience and discretion, addressing challenges people face with daily pills - access issues, practicality, embarrassment, or difficulties due to circumstances like homelessness or domestic violence.
* Crucial Note: The injection should be used in combination with safer sex practices like condom use.
* Cost: The NHS has secured a discount from the manufacturer, though the list price is around £7,000 per patient per year.
* Who it's for: The jab will be considered for adults and adolescents with a healthy weight who are at high risk of sexually acquired HIV.
In essence, this is a significant step forward in HIV prevention, offering a more accessible and convenient option for those at risk.